A patient with Leiden v mutation, multiple sclerosis, psoriasis, and sicca syndrome: Could celecoxib and fingolimod adversely affect the heart?

Cardiovascular Toxicology

Volumn 12, Issue 3, 2012, Pages 266-272

  Cocco, G ^a  

^a Cardiology Office   (Switzerland)

Author keywords

Autoimmune diseases; Celecoxib; Congestive heart failure; Endocarditis; Fingolimod; TNF blockade

Indexed keywords

AMLODIPINE; BIOLOGICAL PRODUCT; BLOOD CLOTTING FACTOR 5 LEIDEN; CELECOXIB; CIPROFLOXACIN; DERMATOLOGICAL AGENT; FINGOLIMOD; FUROSEMIDE; GLYCERYL TRINITRATE; HYALURONIC ACID; HYDROCHLOROTHIAZIDE; LOSARTAN; METOPROLOL;

ABDOMINAL PAIN; ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG TOLERABILITY; ENDOCARDITIS; EYE DISEASE; FEVER; FOLLOW UP; GENERAL PRACTITIONER; GENETIC DISORDER; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; LEIDEN V MUTATION; LEUKOCYTE COUNT; MALE; MANAGED CARE; MEDICAL DECISION MAKING; MEDICAL HISTORY; MEDICAL SPECIALIST; MITRAL VALVE REGURGITATION; MULTIPLE SCLEROSIS; MYALGIA; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SIDE EFFECT; SJOEGREN SYNDROME; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TRANSTHORACIC ECHOCARDIOGRAPHY; VOMITING;

ARTHRITIS, PSORIATIC; ATRIAL FIBRILLATION; AUTOIMMUNE DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG THERAPY, COMBINATION; FACTOR V; HEART; HEART DISEASES; HEART FAILURE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MULTIPLE SCLEROSIS; MUTATION; MYOCARDIUM; PROPYLENE GLYCOLS; PYRAZOLES; SJOGREN'S SYNDROME; SPHINGOSINE; SULFONAMIDES;

EID: 84864693327     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-012-9166-y     Document Type: Article

References (17)

1. Gasparyan, A. Y., Stavropoulos-Kalinoglou, A., Mikhailidis, D. P., Toms, T. E., Douglas, K. M., & Kitas, G. D. (2010). The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Current Vascular Pharmacology, 8, 437-449.
2. Schneider, S., Schmitt, G., & Richter, W. (2006). Prevalence and correlates of inflammatory arthritis in Germany: Data from the First National Health Survey. Rheumatology International, 27, 29-38.
3. John, H., Kitas, G., Toms, T., & Goodson, N. (2009). Cardiovascular comorbidity in early rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology, 23, 71-82.
4. John, H., Toms, T. E., & Kitas, G. D. (2011). Rheumatoid arthritis: Is it a coronary heart disease equivalent? Current Opinion in Cardiology, 26, 327-333.
5. Gasparyan, A. Y., Ayvazyan, L., Cocco, G., & Kitas, G. D. (2012). Adverse cardiovascular effects of antirheumatic drugs: Implications for clinical practice and research. Current Pharmaceutical Design, 18, 1543-1555.
6. Wolfe, F., & Michaud, K. (2004). Heart failure in rheumatoid arthritis: Rates, predictors, and the effect of anti-tumor necrosis factor therapy. American Journal of Medicine, 116, 305-311.
7. Sarzi-Puttini, P., Atzeni, F., Shoenfeld, Y., & Ferraccioli, G. (2005). TNF-alpha, rheumatoid arthritis, and heart failure: A rheumatological dilemma. Autoimmunity Reviews, 4, 153-161.
8. Ontaneda, D., & Cohen, J. A. (2011). Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Review of Clinical Pharmacology, 4, 567-570.
9. Pelletier, D., & Hafler, D. A. (2012). Fingolimod for multiple sclerosis. The New England Journal of Medicine, 366, 339-347.
10. Marin-Garcia J, Goldenthal MJ, Moe (2007) Post-genomic cardiology. Elsevier Academic Press, NY, 228.
11. Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006). Risk of myocardial infarction in patients with psoriasis. Journal of American Medical Assoscia-tion, 296(1735-174), 1. doi:10.1001/jama.296.14.1735.
12. Anema JM, Eijenbrok MW, Faes TJC, Heimans JJ, Lanting, Polman CH. Cardiovascular autonomic function in multiple sclerosis. Journal of Neurol Sciences 1991;104:129-134. doi. 10.1016/0022-510x(9190301-M.
13. Flachenecker, P., Reiners, K., Krauser, M., Wolf, A., & Toyka, K. V. (2001). Autonomic dysfunction in multiple sclerosis is related to disease activity and progression of disability. Multiple Sclerosis, 7, 327-334. doi:10.1177/135245850100700509.
14. Lisi, S., Sisto, M., Lofrumento, D. D., & D'Amore, M. (2011). Sjögren's syndrome autoantibodies provoke changes in gene expression profiles of inflammatory cytokines triggering a pathway involving TACE/NF-jB. Laboratory Investigation. doi: 10.1038/labinvest.2011.190.
15. http://www.drugs.com/sfx/celebrex-side-effects.html
16. Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., et al. (2005). Infective endocarditis. Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America. Circulation, 112, 2373. doi:10.1161/CIRCULATIONAHA.105. 167942.
17. http://www.drugs.com/sfx/mitoxantrone-side-effects.htm